$INO Normally, positive results from a clinical study serve as a positive catalyst for a biotech stock like Inovio. And Inovio's share price did jump 5% in early trading on Friday. However, when the overall market falls as it did today, it's hard for individual stocks to swim against the tide. In addition, investors appear to be much more heavily focused on Inovio's COVID-19 program than anything else right now. Despite today's sell-off, Inovio's results for the INO-5401/INO-9012/Libtayo combo were quite good. The company reported a 70% survival rate after 18 months for one group of patients with glioblastoma, an aggressive type of brain cancer. It also announced a 50% survival rate after 18 months for patients in a group that had a more difficult-to-treat type of glioblastoma. Ino stated that the combo of INO-5401 and INO-9012 "demonstrated a well-tolerated safety profile" when given with radiation and chemotherapy drug temozolomide as well as with Libtayo.
  • 11
11 Likes